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What is sleep, and why do we do it? Surprisingly, some of the main functions of sleep are 
relatively unknown. One thing that is known about sleep is that it is vitally important; this can be 
assumed from its highly conserved nature across the entire animal kingdom. Proper sleep is 
essential for optimal physical and mental health. Sleep disorders impact the brain as well as overall 
health in many ways (Capezuti, 2016). Disrupted sleep can be caused by multiple different diseases 
and disorders. In today’s 24/7 society, access to technology and availability of entertainment at all 
times has contributed to a significant decrease in average sleep time over the past 30 years (Ferrie 
et al., 2011). Along with this decrease in average night’s sleep, the prevalence of sleep disorders 
in the general population has grown and is continuing to grow at an alarming rate (Ferrie et al., 
2011). As important as sleep is, it is surprising that the purpose and mechanisms behind sleep are 
widely unknown. It is imperative to study sleep disturbances and the diseases that are often related 
to these disturbances in order to further the understanding of the mechanism of sleep as well as 
emphasize the importance of sleep in order to improve the health of society.  
One disease that has shown to have 
consistent sleep disruptions alongside its main 
symptoms is Alzheimer’s Disease. Alzheimer’s 
Disease (AD) is a devastating neurodegenerative 
disease that is defined by memory and cognition 
impairments, and it affects nearly 5.7 million 
people in the United States alone (Alzheimer's 
Disease: Get The Facts 2020). AD cases have 
grown over 145% in the past 20 years, and the 
disease is projected to affect 3 times as many 
people by the year 2050 (Alz.org: Facts and 
Figures). Although the disease is growing in 
prevalence, little is known about the cause and 
cure for AD. In an AD brain, the development of 
large plaques composed in part of protein 
fragments and tangles composed largely of 
hyperphosphorylated tau protein are seen, which form the hallmarks of AD – Amyloid plaques 
(Aβ) and neurofibrillary tangles. The Aβ protein found in plaques is the result of abnormal 
cleavage of a normal, healthy amyloid precursor protein by specific secretases. The Aβ cleavage 
can result in different sizes of the protein, including Aβ 40 and Aβ 42. The Aβ peptides can form 
soluble oligomers or misfold and aggregate as insoluble plaques that stick to the brain and may 
cause a lot of damage to the nerves surrounding them (Schmidt et al., 2009), while other evidence 
suggests the soluble oligomers are much more toxic (Yang et al., 2017). These processes 
additionally cause neuroinflammation throughout the brain. Figure 1 shows an image of what an 
AD brain with Aβ plaques and neurofibrillary tangles looks like compared to a normal, healthy 
brain. Nerve damage due to this Aβ plaque build-up as well as neuroinflammation may be a cause 
of the severe cognitive decline seen with the development of AD (Schmidt et al., 2009).  
The Aβ protein is produced in healthy brains as well, however it is often cleared out of the 
brain as a waste product (Yoon et al., 2021). Waste clearance in the brain is believed to occur 
during sleep via the glymphatic system; this system’s purpose is to clear soluble proteins and 
metabolites from the central nervous system using a network of tunnels within the vascular system 
Figure 1. Illistrational example of amyloid beta plaques and 
neurofibrillary tangles in an AD brain (Amyloid plaques and 
neurofibrillary tangles). 
(Jessen et al., 2015). Lack of sleep could therefore influence Aβ clearance in the brain. AD patients 
have often been shown to have disrupted sleep symptoms associated with their disease. Previous 
research has shown up to 40% of people suffering from AD also show sleep disruption along with 
the hallmark cognitive symptoms (Lloret et al., 2020). The sleep pattern of an AD patient is often 
fragmented with frequent nighttime awakening and daytimes naps (Lloret et al., 2020). Due to this 
disrupted sleep and decreased availability for waste clearance from the brain, these sleep 
symptoms may be a contributing factor in the progression of AD. Previous studies have indicated 
that alterations in the daily sleep-wake cycle precede the diagnosis of AD by many years (Bliwise, 
2004). A role for sleep disruption in AD pathology has also been supporting sleep mouse models 
of AD, which accelerates various pathological markers. However, these studies did not mimic the 
sleep disruption patterns found in people with AD. Therefore, the first goal of this research was to 
investigate whether the disrupting sleep patterns 4 times/day would provide a better model of AD 
patients, and the role disrupted sleep might play in the progression of disease itself. This 
experiment investigated whether chronic disruption of daily sleep-wake cycles with sleep 
fragmentation increased Aβ 40 and 42 levels and neuroinflammation in the brains of transgenic 
AD mice (3xTgAD). The 3xTgAD mice express 3 mutations, the PS1m146v, APPSwe, and tauP301L 
transgenes, that are associated with familial, early-onset AD, causing expression of Aβ plaques 
and tau pathology (Sterniczuk et al., 2010). While mice sleep differently than people, with highly 
polyphasic sleep, and a majority of sleep during the light period, they are still good models for 
sleep studies because sleep disruptions in rodents show comparable cognitive impairments to 
humans after sleep disruption, and the basic neurophysiology of sleep is very similar across all 
mammals. The hypothesis for this study was that sleep fragmentation will increase Aβ 40 and 42 
levels as well as neuroinflammation in the brain when compared to the non-sleep fragmented group 
of transgenic 3xTgAD mice. 
If sleep fragmentation may lead to greater progression of AD, then increasing sleep amount 
or quality may help slow the progression of AD. Often times pharmaceuticals are used to help 
patients who suffer from sleep disorders, but those come along with undesirable side effects and 
have not been shown to treat the underlying sleep disorder (Pagel & Parnes, 2001). Another option 
for sleep enhancement is using mechanical movement. This idea stems from the common way that 
parents help their babies go to sleep with gentle rocking. Similarly, many people tend to doze off 
in a car or on a boat due to the nature of slight, consistent movement. Is this phenomenon of rocking 
inducing sleep scientifically sound and significant? This phenomenon has only just recently been 
observed in rodents; rodents do not typically rock their young to sleep, but the idea is that the 
movement could mimic movements of the mother when the babies are in utero. Due to the high 
similarities between mouse and human sleep and overall physiology, could a mouse model show 
improved sleep after mechanical rocking? These are the questions that inspired the next research 
question of this project.  
The scientific basis behind gentle rocking and sleep lies in the vestibular system, which is 
located in the ear with the main purpose of detecting linear and angular motion of the head as well 
as orientation and perception (Besnard et al., 2018). The vestibular organs have direct inputs into 
the suprachiasmatic nucleus (SCN), which is known as the master circadian clock in the brain with 
large influences on sleep/wake cycles of both humans and mice (Besnard et al., 2018). 
Additionally, the vestibular organs play an important role in synchronizing the fluctuations of body 
temperature seen among biological rhythms (Besnard et al., 2018). So, when the vestibular organs 
sense a consistent, light movement, these signals are believed to be transmitted to the SCN and 
influence sleep (Besnard et al., 2018). A previous study found that gentle rocking using a 
mechanical rocking platform may help consolidate sleep using a mouse model (Kompotis et al., 
2019). The study by Kompotis and colleagues used a rocking platform at multiple different 
frequencies to investigate how this method could be used to improve sleep in mice. This current 
study aimed to investigate whether mechanical rocking could be used to improve sleep using a 
mouse model, and whether this method would be successful in helping slow the progression of 
AD. The hypothesis of this experiment was that slight rocking using a shaker platform will improve 




Sleep Fragmentation Study 
 For this experiment, 8-month-old female 3xTgAD mice were used as the model. Only 
female mice were used in this study due to females expressing a more consistent phenotype as well 
as the ease of being able to re-group house females without fear of injury from fighting. Mice were 
kept in standard group housing with four mice to a cage during the protocol, except for weeks 1 
and 4 when sleep monitoring required each mouse to be housed individually. The light conditions 
were standard 12:12, with lights on at 7:00 AM and lights off at 7 PM. All mice were given 
standard mouse chow and water ad libitum throughout the entire protocol.   
Sleep was monitored using the PiezoSleep System (Signal Solutions LLC). The PiezoSleep 
system consists of piezoelectric films placed underneath the floor of the mouse cage (Figure 2). 
These films detect changes in pressure caused by movement and change these pressures into 
electrical signals that can be analyzed to detect sleep. The system is precise enough to detect 
breathing and has been shown to have a classification accuracy of >90% (Mang et al., 2014). This 
option was chosen as it is less invasive than the standard surgery to insert EEG connection in the 
brain.  
Mice were sorted into two separated groups: a sleep 
fragmentation group (SF) and an undisturbed sleep 
group (US). Both groups consisted of 8 mice each. The 
protocol was 4 weeks long. During the first and fourth 
weeks, mice were kept in individual cages equipped 
with piezoelectric sensors in order to monitor sleep and 
sleep disruption. During the second and third weeks, 
mice were group housed with no sleep monitoring.  
The sleep fragmentation group underwent four one-
hour sleep fragmentation sessions each day, five days a 
week, for four weeks. During weeks two and three, SF 
mice were removed from group housing and placed in 
novel, individual cages for the sleep fragmentation sessions and then placed back into group 
housing immediately after the sleep fragmentation sessions concluded. The one-hour sleep 
fragmentation sessions consisted of keeping the mice awake by introducing novel toys such as 
Legos or cardboard tubes and using a paintbrush to lightly disturb them. The US group mice were 
left undisturbed during the sleep fragmentation intervals. After the four-week protocol, all mice 
were anesthetized using CO2 asphyxiation and brains were harvested after decapitation. The 
hippocampus and cortex of the brains were extracted and stored frozen at -80°C.  
Brain matter was analyzed for Aβ 40 and 42 levels and neuroinflammatory markers (reactive 
microglial, reactive astrocytes, inflammatory cytokines, and inflammatory chemokines). Aβ 40 
Figure 2. The piezoelectric films used to record sleep 
for both the sleep fragmentation and sleep 
enhancement studies (www.sigsoln.com). 
and 42 levels were quantified using sandwich ELISAs, using two different assay buffers, 
radioimmunoprecipitation assay buffer (RIPA) and 0.2% diethylamine (DEA). RIPA buffer was 
used to measure aggregated and protofibrillar Aβ, while the DEA buffer measured diffusible Aβ 
monomers and oligomers. Neuroinflammatory markers were quantified using RNeasy mini 
columns as well as High-Capacity cDNA Reverse Transcription Kits. Sleep data was collected 
from the piezoelectric system in 30-minute bins. For each 30-minute interval, the percent sleep 
was recorded as an average of that 30-minute bin. Data was analyzed using GraphPad Prism and 
2-way repeated measures ANOVA by group and time.  
 
Sleep Enhancement Study  
For this experiment, three seven-month-old C57/BL6 (commonly referred to as black 
6) mice were used as the model. One mouse that was used was a male and the other two were 
female. All mice were kept on a 12:12 light dark schedule (lights on 7:00 AM – 7:00 PM) in 
standard group housing with standard mouse chow and water ad libitum. The protocol was 
performed on the mice one at a time. During the four-day experiment, the mouse was housed 
individually in a cage equipped with piezoelectric system film (Signal Solutions LLC) and placed 
upon the MouseQwake platform (Signal Solutions LLC). The set-up of the cages was as follows: 
the MouseQwake platform rested on a shelf, with a piezoelectric film directly on top of it, and then 
the standard mouse cage with food and water placed on top of the film. A large rubber band was 
used to secure the cage to the MouseQwake platform to ensure that nothing fell out of place while 
the platform was rocking. Additionally, a metal water bottle stand was screwed into the base of 
the MouseQwake platform to ensure that the rocking wouldn’t cause the water bottle to leak.  
 For the four-day protocol, the first day was an acclimation day where the mouse was placed 
into the experimental cage set-up and no data was analyzed. The second day was a baseline day, 
where no rocking occurred, and the recording began at lights on (7:00 AM). Day three was the 
experimental day. The MouseQwake platform rocked from 7:00 AM-7:00 PM at 2 Hz frequency 
and 30 m amplitude. The last day, day four, was a recovery day where no rocking occurred, and 
the data analysis ended at 7:00 AM the next morning. Each mouse’s tail was then marked using 
sharpie before returning it to group housing after the four-day protocol was complete. Sleep data 
was analyzed in 60-minute bins, with average total percent sleep for the 60-minute interval 
recorded. Sleep stats and GraphPad Prism were used to statistically analyze data (2-way ANOVA) 




Sleep Fragmentation Study 
 Results from the piezoelectric monitoring showed that sleep/wake patterns were 
successfully altered using the sleep fragmentation sessions. Total sleep percent was significantly 
reduced during the one-hour sleep fragmentation sessions (p<0.01). Figure 3 illustrates the average 
percent sleep for each hour on week one and week four. During week one, light phase sleep for 
the SF group was significantly decreased compared to US; however, week one dark phase sleep 
was not significantly affected. In contrast, during week four, light phase sleep as well as dark phase 
sleep was significantly altered for the SF group compared to the US group. Additionally, during 
week four, mice had a higher percent sleep during the sleep fragmentation intervals. Sleep bout 
duration was also affected by the sleep fragmentation intervals.  During both week one and week 
four, sleep bout durations were significantly decreased when compared to the US decreased. Sleep 
bout length as well as sleep 
percent was increased 
during the dark phase for 
the SF group compared to 
US.  
 Results from the 
ELISA analysis showed 
that the SF mice trended to 
having higher levels of 
both protein sizes in the 
hippocampus. However, 
only the Aβ 42 in the RIPA 
buffer produced significant 
results in the hippocampus. 
Chronic SF significantly 
increased the hippocampal 
levels of RIPA-soluble Aβ 
40 by 20% and Aβ 42 by 
64% (significance p<0.05) 
when compared to US. The 
DEA-soluble Aβ 40 and 42 
did not produce 
significance. This is shown 
in Figure 4. For the cortex, 
the data trended higher 
levels in the SF group 
however none of the results 
were significant. 
 Analysis of neuroinflammation markers showed higher levels in the hippocampus of the 
SF group compared to US, however this result was not statistically significant. Figure 5 shows the 
composite z-score for reactive microglial, reactive astrocytes, inflammatory cytokines, and 
inflammatory chemokines in the hippocampus and neocortex.  
 
Sleep Enhancement Study 
  Results from the three trials of sleep enhancement of the MouseQwake platform showed 
that slight rocking did not increase percent sleep or sleep bout lengths. Table 1 shows the average 
percent sleep values for baseline, experimental, and recovery days. A small trend can be seen that 
shows slightly less percent sleep during the light phase on the experimental day (when the shaker 
was rocking the mouse) and then slightly more sleep during the dark phase after the shaker is 
turned off. Figure 6 shows the total sleep across all three days as well as the average light and dark 
phase sleep percent averaged over the three days. There was no significant difference between the 
percent sleep for baseline, experimental, and recovery. There was a trend towards a greater amount 




Figure 3. Chronic sleep fragmentation alters the daily sleep profile.  Values represent 
the mean + S.E.M. sleep percentage for 30 min bins, N=8/group, for piezoelectric 
recordings during weeks 1 and 4. Horizontal white and black bars at the bottom 
indicate the light and dark phases. 
Discussion 
 
Sleep Fragmentation Study 
 This study established that the 
3xTgAD mouse provides a good model 
for the disrupted sleep/wake patterns 
demonstrated in AD patients. The 
findings of this study show that the sleep 
fragmentation sessions successfully 
reduced sleep percent during the SF 
intervals. Overall, it was found that 
protein levels of Aβ 40 and 42 as well as 
neuroinflammation markers in the 
hippocampus were significantly higher 
in SF mice, leading to the progression of 
AD neuropathology. Decreased sleep 
and shortened/fragmented sleep cycles 
may play a role in limiting the amount 
of Aβ 40 and 42 cleared from the brain, 
resulting in increased Aβ deposition and 
neuroinflammation in the brain, 
especially in the hippocampus. 
  Few previous studies have 
investigated how sleep fragmentation alters 
daily sleep patterns. The one-hour sleep 
fragmentation intervals used in this study are 
comparable to the frequent nighttime 
awakenings experienced by AD patients, 
more so than previous sleep deprivation 
studies. The results from the sleep data 
showed that by week four, SF mice had 
altered sleep in the dark phase as well as light 
phase, indicating that the sleep fragmentation 
sessions altered the sleep/wake patterns. 
These findings also suggested that the SF 
group experienced longer sleep bouts during 
the dark phase during recovery sleep in 
response to chronic sleep fragmentation. During week four, a greater percent sleep was observed 
during the sleep fragmentation session when compared to week one. This indicated that the SF 
mice were having a harder time staying awake during the sleep fragmentation sessions, especially 
towards the end of the light phase, demonstrating the cumulative effects of four weeks of chronic 
sleep fragmentation. Although the overall reduced total sleep that AD patients often experience 
was not seen in this mouse model, the sleep fragmentation protocol did mimic the fragmented 
nature of the human AD patient’s sleep pattern. 
  Analysis of Aβ 40 and 42 showed increases from both buffers in the hippocampus of the 
SF mice compared to the US mice. However, only the RIPA soluble Aβ 42 in the hippocampus 
Figure 4. Aβ 40 and 42 levels in RIPA and DEA buffers for the cortex and 
hippocampus. Approximately a 100-fold difference was found between the 
cortex and hippocampus. Vertical bars represent mean +/-SEM. Significance 
was found for Aβ 42 in RIPA buffer (p<0.05).  
Figure 5. Relative change ( z-score) of neuroinflammatory markers. 
Red is SF and black in US. A significant result was found for reactive 
microglial signature (p=0.0461).  
was significant. A longer sleep fragmentation protocol may be useful to produce significant results 
for the DEA buffer and RIPA Aβ 40, as AD is a disease that accumulates over many years. These 
results suggest that continuing the study for a longer period of time may cause additional Aβ build-
up and therefore produce more significant results. Additionally, the Aβ 42 protein has been shown 
to have greater neurotoxicity in the brain, so it may be more influential in the progression of 
cognitive symptoms associated with AD (Schmidt et al., 2009).   
 The neuroinflammatory markers were found in higher levels in the brains of SF mice, 
indicating that more damage to neurons were causing greater inflammation as a result of chronic 
sleep fragmentation. These results suggest that chronic sleep fragmentation as well as greater 
levels of Aβ drive inflammation. Although results showed trends toward higher levels of 
neuroinflammation markers, there was a large amount of variability between subjects within both 
groups. So, more trials with larger sample sizes may help make stronger conclusions about 
neuroinflammatory markers and AD pathology.  
 This study had some limitations. Only female mice were used, and this could be an issue 
because male and female mice tend to have different sleep profiles. Another limitation is that only 
the 3xTgAD transgenic model was investigated; other transgenic AD mouse models, such as the 
APP mouse model would be useful to investigate using this same protocol. Additionally, only 
hippocampal and cortex Aβ and neuroinflammatory levels were measured. AD pathology comes 
along with other defects in the brain such as neurofibrillary tangles, neuronal death, and cognitive 
impairments. These hallmarks of AD were not studied in this experiment, so the effect of chronic 
sleep fragmentation on these facets remain unknown. Another potential limitation is the use of the 
piezoelectric system. Although this system has the advantage of being non-invasive, the ability to 
study different phases of sleep such as REM and slow wave sleep are lost by using this method.  
 Altogether, the 3xTgAD mouse model provides a model that mimics AD patient when 
exposed to chronic sleep fragmentation. Chronic sleep fragmentation, as seen in AD patients, 
stimulates greater accumulation of Aβ as well as neuroinflammation in the hippocampus of the 
brain. Future rodent studies could utilize both sexes and other AD models, with larger sample 
sizes, and analyzing other aspects of AD such as memory and cognition as well as neuronal death 
would be beneficial to furthering the understanding of the relationship between sleep and AD. If 
these future rodent studies continue to support the findings from this experiment, then sleep 
enhancement and consolidation may be a potential therapeutic method for slowing the progression 
of AD pathology.  
 
Sleep Enhancement Study 
  Since it was found that sleep fragmentation expedited the development of AD pathologies 
in the brain, this study aimed to explore whether sleep enhancement could be used to slow the 
progression of AD pathology in the brain. First, a sleep enhancement method must be determined. 
This experiment intended to determine if slight rocking using a mechanical shaker platform, 
MouseQwake, could improve the sleep of C57/BL6 mice. Significant alterations of sleep were not 
found when using the mechanical shaker. Due to the very small sample size (n=3) used for this 
experiment, limited conclusions can be made. The continuation of this experiment with a larger 
sample size is crucial in order to fully understand the relationship between slight rocking and sleep  
improvement. A very small trend can be observed in the data, showing that the recovery day had 
slightly increased amounts of light phase sleep and slightly less dark phase sleep. This may indicate 
that the slight rocking from the MouseQwake platform caused a slight sleep disruption for the 
mouse, leading to greater amounts of light phase sleep on the third recovery day. The slight 
increase in dark phase sleep after the 12 hours of rocking may also indicate sleep recovery from 
disruption due to the shaker.  
 A previous study, by Kompotis et al. in 2019, found significant improvement in sleep when 
using mechanical rocking on mice. This studied used lateral mechanical rocking of twenty-three 
C57BL/6J mice monitored using EEG. This studied explored multiple different frequencies but 
found that 1 Hz and greater had the most significant impact on sleep structure. This study found 
that slight rocking, which influences the body’s vestibular system, has a significant impact on 
improving NREM sleep. The vestibular system is known to project directly to the brain’s central 
 Baseline Experimental Recovery 
Light phase sleep 53.8% 52.9% 56.4% 
Dark phase sleep 31.0% 32.2% 27.9% 
Total sleep 42.4% 42.6% 42.1% 
Table 1. This table shows the average percent sleep values for all three days of the protocol (n=3). 
Figure 6. This figure shows the percent sleep values across the three days. No significant results were found. 
Although, the recovery day trended to have greater light phase sleep and less dark phase sleep. 
circadian clock, the SCN. So, this mechanism of action should have a huge influence on the body’s 
daily sleep/wake cycles.  
The failure to find significant results for this study may be attributed to the fact that this 
experiment did not look at NREM and REM sleep cycles, but only sleep percent and mean sleep 
bout length as a whole. Perhaps the total sleep time and sleep bouts were unaffected, however the 
theta waves in NREM may have increased. This was not measured using the piezo system, so this 
would be something important to investigate with future studies. Another limitation to this study 
was that mice with sleep disorders to begin with were not studied. The sleep percentages recorded 
for the mice were relatively average for a normal, healthy mouse. Unfortunately, a good mouse 
model for insomnia or any other sleep disorder has not yet been discovered. A mouse that already 
experiences healthy sleep may be difficult to try to use when trying to improve sleep. If the mouse 
is already obtaining normal levels of sleep, then increasing that sleep amount may be difficult.  
 Another drawback to this experiment was the equipment used. This MouseQwake system 
was a prototype, and this was the first time it was used for this application. The exact frequency 
was slightly off, so the desired frequency had to be felt by hand which may be off due to human 
error. Additionally, every 30 seconds, the shaker “hiccupped” slightly, causing a very slight 
inconsistency in its rocking. This slight blip may have been enough to disturb a resting mouse’s 
sleep. Additionally, the equipment made a slight humming noise that may have disturbed the 
mouse in an otherwise quiet environment.  
Additional trials will be conducted in order to further the results of this study. Since the 
current protocol did not successfully show sleep enhancement, future plans to alter the frequency 
(2 Hz) and amplitude (30 m) settings used are in place in order to investigate whether different 
frequencies/amplitudes may help improve sleep. Slight rocking may be sleep enhancing, but only 
at the correct settings. Studies that have found successful sleep enhancement with a shaking device 
(ex. Kompotis et al., 2019) have used a platform that uses lateral movement in order to have a 
more “true rocking” motion, whereas the platform used in this current experiment used vibrations 
to induce the simulation of shaking. So, it is important to continue this experiment using different 
settings as well as reducing the noise of the equipment and any other confounding variables that 
may be affecting sleep. If changing the amplitude and frequency of the shaker is not proven 
successful, then possibly introducing a new type of mechanical device that allows for horizontal 
and vertical movement, in order to create a true rocking motion, would be beneficial. The future 
goal of this study is to successfully enhance sleep using mechanical rocking and test to see if 
enhanced sleep from mechanical rocking can slow the progression of AD pathology using 
transgenic 3xTgAD mouse models. 
 
Reflection  
 Participation in this research project has been a huge learning experience for me. First 
and foremost, I have learned about the process of real-life science: trial and error, success and 
failure. Not that I would consider my sleep enhancement trials a failure, but I did learn how to 
adapt and ask new questions when the expected or desired results did not occur. I have learned to 
critically think and create my own protocol rather than simply follow one that already existed. 
The lessons I have learned from conducting research are ones I will carry with me throughout my 
future education and career. I want to thank all of my professors and advisors that have helped 
me achieve my goals throughout my undergraduate career. I want to specially thank my research 
mentors, Dr. Bruce O’Hara, Dr. Marilyn Duncan, and (soon to be Dr.) Ren Guerriero, for all the 
time, effort, and advice they have given me over the past 3 years.   
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